EGFR and lung cancer: Besides TNO155, another SHP2i, RMC-4630, is in clinical trials with cobimetinib (an MEKi) in relapsed or refractory solid tumors, and with osimertinib in EGFR+, locally advanced, or metastatic non–small cell lung cancer (ClinicalTrials.gov NCT03989115).